The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
JAVELIN ovarian PARP 100 study design: Phase III trial of avelumab + chemotherapy followed by avelumab + talazoparib maintenance in previously untreated epithelial ovarian cancer.
 
Ramez Nassef Eskander
Honoraria - Clovis Oncology
Speakers' Bureau - AstraZeneca/MedImmune; Clovis Oncology; Genentech/Roche
Travel, Accommodations, Expenses - AstraZeneca/MedImmune; Clovis Oncology; Genentech/Roche
 
Jonathan A. Ledermann
Honoraria - AstraZeneca/MedImmune; Roche
Consulting or Advisory Role - AstraZeneca/MedImmune; Clovis Oncology; Pfizer; Roche
Speakers' Bureau - Clovis Oncology; Pfizer
Research Funding - AstraZeneca
 
Michael J. Birrer
Consulting or Advisory Role - Acceleron Pharma; Merrimack; Oxigene; Roche/Genentech; Sanofi; Threshold Pharmaceuticals
 
Keiichi Fujiwara
Honoraria - Bayer; Chugai Pharma; Daiichi Sankyo; Eisai; Janssen Oncology; Kyowa Hakko Kirin; Lilly Japan; Nippon Kayaku; Ono Pharmaceutical; Taiho Pharmaceutical; Zeria Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Chugai Pharma; Eisai; MSD; Pfizer; Taiho Pharmaceutical; Takeda
Research Funding - AstraZeneca (Inst); Chugai Pharma (Inst); Eisai (Inst); GlaxoSmithKline (Inst); Immunogen (Inst); Kaken Pharmaceutical (Inst); Lilly (Inst); MSD (Inst); Oncotherapeutics (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst); Zeria Pharmaceutical (Inst)
 
Stephanie Gaillard
Honoraria - Merck; Merck
Consulting or Advisory Role - Genentech/Roche; Merck; Pfizer; Tesaro
Research Funding - Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Gradalis (Inst); Iovance Biotherapeutics (Inst); Merck (Inst); PharmaMar (Inst); TetraLogic Pharmaceuticals (Inst)
Patents, Royalties, Other Intellectual Property - Sermonix Pharmaceuticals
 
Gary Edward Richardson
Research Funding - AstraZeneca (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); CBT Pharmaceuticals (Inst); Corvus Pharmaceuticals (Inst); Merck (Inst); Novotech (Inst); Pfizer (Inst); Roche/Genentech (Inst); Takeda (Inst)
 
Caimiao Wei
Employment - Pfizer
 
Mahadi Ali Baig
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Fabian Zohren
Employment - Pfizer; Takeda
Stock and Other Ownership Interests - Pfizer; Takeda
 
Bradley J. Monk
Leadership - US Oncology
Honoraria - Abbvie; Advaxis; Amgen; Amgen; AstraZeneca; Bayer; Biodesix; Biodesix; Clovis Oncology; Genmab; GlaxoSmithKline; Gradalis; Immunogen; Incyte; Insys Therapeutics; Janssen; Mateon Therapeutics; Merck; Myriad Pharmaceuticals; Nucana; Oxigene; Oxigene; Perthera; Pfizer; Precision Oncology; Roche/Genentech; Samumed; Samumed; Takeda; Tesaro; VBL Therapeutics
Consulting or Advisory Role - Abbvie; Advaxis; Amgen; AstraZeneca; Bayer; Biodesix; Cerulean Pharma; Clovis Oncology; GlaxoSmithKline; Gradalis; Immunogen; Incyte; Insys Therapeutics; Mateon Therapeutics; Merck; Myriad Pharmaceuticals; Nucana; Oxigene; Perthera; Pfizer; Precision Oncology; Roche/Genentech; Tesaro; Verastem; Vermillion
Speakers' Bureau - AstraZeneca; Clovis Oncology; Janssen; Roche/Genentech; Tesaro
Research Funding - Advaxis (Inst); Amgen (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Genentech (Inst); Immunogen (Inst); Janssen (Inst); Lilly (Inst); Morphotek (Inst); Novartis (Inst); Nucana (Inst); Pfizer (Inst); Regeneron (Inst); Tesaro (Inst)